Journal Information
Vol. 36. Issue 1.
Pages 71 (January 2017)
Download PDF
More article options
Vol. 36. Issue 1.
Pages 71 (January 2017)
Letter to the Editor
Open Access
Determinants of safety of early discharge after primary percutaneous coronary intervention
Determinantes de segurança na alta antecipada após intervenção coronária percutânea primária
Levent Cerit
Department of Cardiology, Near East University, Nicosia, Cyprus
Article information
Full Text
Download PDF
Full Text
To the Editor,

I read the article entitled “Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction” by Tralhão et al.,1 published in Revista Portuguesa de Cardiologia in 2015, with great interest. The investigators reported that the Zwolle risk score (ZRS) showed excellent discriminative ability to identify low-risk ST-elevation myocardial infarction (STEMI) patients who could be safely discharged within 72 hours of primary percutaneous coronary intervention (PPCI).1

According to current recommendations, patients with a ZRS ≤3 are considered at low risk and are eligible for discharge 72 h after PPCI.2 The ZRS is based on age, heart failure signs, localization of infarction, ischemia time, number of diseased coronary vessels, and post-procedural angiographic result, and has been shown to predict 30-day post-discharge mortality.2

Natriuretic peptides have been shown to provide additional prognostic information in patients with STEMI.3 Brain natriuretic peptide (BNP) levels can act as a global marker reflecting myocardial damage and heart failure.3 Ganovska et al.4 reported that patients with high ZRS and BNP ≤200 pg/ml had similar mortality and hospital stay to those with low ZRS. In this context, it might be useful to measure serum natriuretic peptide levels due to their prognostic significance.

Microvascular obstruction (MVO) occurs frequently in patients with STEMI even after prompt revascularization of the culprit artery. Depending on the severity of the ischemic injury, microvascular injury can lead to MVO, and MVO can lead to intramyocardial hemorrhage (IMH). Microvascular damage and reperfusion injury after STEMI are important markers of outcomes. Cardiac magnetic resonance (CMR) provides a comprehensive analysis of myocardial infarction, including assessment of myocardial scar, MVO, and IMH.5 In this context, it might be beneficial to assess MVO and IMH by CMR in order to identify patients eligible for early discharge.

Conflicts of interest

The author has no conflicts of interest to declare.

A. Tralhão, A.M. Ferreira, S. Madeira, et al.
Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.
Rev Port Cardiol, 34 (2015), pp. 535-541
T. Melberg, M. Jørgensen, S. Ørn, et al.
Safety and health status following early discharge in patients with acute myocardial infarction treated with primary PCI: a randomized trial.
Eur J Prev Cardiol, 22 (2015), pp. 1427-1434
D.A. Schellings, A. Adiyaman, E. Giannitsis, et al.
Early discharge after primary percutaneous coronary intervention: the added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score.
J Am Heart Assoc, 3 (2014), pp. e001089
E. Ganovska, M. Arrigo, K. Helanova, et al.
Natriuretic peptides in addition to Zwolle score to enhance safe and early discharge after acute myocardial infarction: a prospective observational cohort study.
Int J Cardiol, 215 (2016), pp. 527-531
Y.S. Hamirani, A. Wong, C.M. Kramer, et al.
Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis.
JACC Cardiovasc Imaging, 7 (2014), pp. 940-952
Revista Portuguesa de Cardiologia (English edition)

Subscribe to our newsletter

Article options
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email I declare for all purposes that the information provided herein is accurate and correct.